Real-time Estimate
Cboe BZX
11:26:22 2024-07-12 am EDT
|
5-day change
|
1st Jan Change
|
1.455
USD
|
-0.34%
|
|
+14.18%
|
+2.84%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,223
|
441.2
|
234.1
|
244.4
|
-
|
-
|
Enterprise Value (EV)
1 |
861.6
|
183.2
|
72.97
|
193
|
107.6
|
12.81
|
P/E ratio
|
-6.31
x
|
-2.71
x
|
-5.64
x
|
-2.27
x
|
-2.08
x
|
-2.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
60
x
|
1,894
x
|
1,094
x
|
978
x
|
978
x
|
7.91
x
|
EV / Revenue
|
42.3
x
|
786
x
|
341
x
|
772
x
|
430
x
|
0.41
x
|
EV / EBITDA
|
-6.35
x
|
-1.27
x
|
-0.58
x
|
-1.78
x
|
-0.77
x
|
-0.08
x
|
EV / FCF
|
-13.6
x
|
-1.74
x
|
-0.86
x
|
-1.94
x
|
-0.89
x
|
-0.09
x
|
FCF Yield
|
-7.36%
|
-57.4%
|
-116%
|
-51.5%
|
-112%
|
-1,133%
|
Price to Book
|
3.25
x
|
1.69
x
|
0.96
x
|
1.64
x
|
1.15
x
|
0.93
x
|
Nbr of stocks (in thousands)
|
160,298
|
165,875
|
166,010
|
167,406
|
-
|
-
|
Reference price
2 |
7.630
|
2.660
|
1.410
|
1.460
|
1.460
|
1.460
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.38
|
0.233
|
0.214
|
0.25
|
0.25
|
30.88
|
EBITDA
1 |
-135.8
|
-144.6
|
-125.2
|
-108.4
|
-140.5
|
-164.2
|
EBIT
1 |
-135.8
|
-144.8
|
-125.5
|
-108.5
|
-141
|
-128.2
|
Operating Margin
|
-666.49%
|
-62,140.34%
|
-58,631.31%
|
-43,394.4%
|
-56,390.73%
|
-415.05%
|
Earnings before Tax (EBT)
1 |
-136.6
|
-135.2
|
-39.29
|
-110.2
|
-141.4
|
-128.6
|
Net income
1 |
-167.8
|
-152.4
|
-40.22
|
-109.6
|
-139
|
-124.7
|
Net margin
|
-823.56%
|
-65,401.29%
|
-18,796.26%
|
-43,821.52%
|
-55,601.47%
|
-403.8%
|
EPS
2 |
-1.210
|
-0.9800
|
-0.2500
|
-0.6420
|
-0.7033
|
-0.5300
|
Free Cash Flow
1 |
-63.42
|
-105.2
|
-84.38
|
-99.35
|
-120.9
|
-145.1
|
FCF margin
|
-311.24%
|
-45,167.38%
|
-39,428.5%
|
-39,740%
|
-48,361.07%
|
-469.91%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.23
|
-
|
0.17
|
0.024
|
0.038
|
0.037
|
0.172
|
0.087
|
0.018
|
-
|
-
|
-
|
0.3
|
-
|
-
|
EBITDA
1 |
-45.15
|
-33.38
|
-35.34
|
-38.39
|
-37.51
|
-33.15
|
-31.78
|
-26.76
|
-33.46
|
-24
|
-27.3
|
-28.45
|
-28.65
|
-
|
-
|
EBIT
1 |
-45.18
|
-33.44
|
-35.36
|
-38.42
|
-37.56
|
-33.21
|
-31.86
|
-26.83
|
-33.56
|
-24.08
|
-27.3
|
-27.63
|
-29.44
|
-32.53
|
-36.5
|
Operating Margin
|
-19,641.3%
|
-
|
-20,798.24%
|
-160,095.83%
|
-98,855.26%
|
-89,767.57%
|
-18,524.42%
|
-30,843.68%
|
-186,450%
|
-
|
-
|
-
|
-9,813.4%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-48.58
|
-31.92
|
-30.81
|
-33.13
|
-39.32
|
-33.16
|
-31.66
|
43.85
|
-18.32
|
-25.68
|
-27.11
|
-28.02
|
-29.72
|
-32.37
|
-36.44
|
Net income
1 |
-88.88
|
-36.87
|
-36.62
|
-33.89
|
-45.01
|
-33.14
|
-33.04
|
44.24
|
-18.29
|
-26.71
|
-26.65
|
-27.56
|
-29.16
|
-32.41
|
-36.32
|
Net margin
|
-38,642.17%
|
-
|
-21,540%
|
-141,195.83%
|
-118,450%
|
-89,554.05%
|
-19,210.47%
|
50,855.17%
|
-101,622.22%
|
-
|
-
|
-
|
-9,719.8%
|
-
|
-
|
EPS
2 |
-0.6200
|
-0.2400
|
-0.2400
|
-0.2200
|
-0.2800
|
-0.2100
|
-0.2100
|
0.2500
|
-0.1200
|
-0.1700
|
-0.1640
|
-0.1620
|
-0.1600
|
-0.1900
|
-0.2100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/16/22
|
8/15/22
|
11/10/22
|
3/24/23
|
5/11/23
|
8/10/23
|
11/14/23
|
3/28/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
362
|
258
|
161
|
51.4
|
137
|
232
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-63.4
|
-105
|
-84.4
|
-99.4
|
-121
|
-145
|
ROE (net income / shareholders' equity)
|
-71.8%
|
-47.8%
|
-16%
|
-53.1%
|
-59.2%
|
-46.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.350
|
1.570
|
1.460
|
0.8900
|
1.270
|
1.570
|
Cash Flow per Share
2 |
-0.4600
|
-0.6700
|
-0.5300
|
-0.4600
|
-0.5000
|
-0.4200
|
Capex
1 |
0.17
|
0.77
|
0.26
|
2.65
|
3.21
|
3.92
|
Capex / Sales
|
0.85%
|
331.76%
|
121.03%
|
1,060%
|
1,285.87%
|
12.7%
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.46
USD Average target price
9.5
USD Spread / Average Target +550.68% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.55% | 244M | | +23.50% | 47.07B | | +46.90% | 42.06B | | -5.16% | 39.98B | | +36.37% | 33.02B | | -7.79% | 27.9B | | +18.06% | 27.63B | | +47.29% | 14.37B | | +41.91% | 13.45B | | -1.02% | 12.03B |
Other Biotechnology & Medical Research
|